Market Overview - A-shares experienced volatility on February 6, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and the ChiNext Index down 0.73% [1] - The overall market turnover decreased to 2.16 trillion yuan, marking a continuous six-day decline in trading volume [1] Sector Performance - The chemical and new energy sectors led the market, while the pharmaceutical sector showed relative resilience. Consumer goods experienced a pullback, and technology continued to be sluggish [1] - The chemical ETF (516020) saw a significant inflow of 199 billion yuan, with a daily gain of 2.37% after reaching a peak increase of 3.45% during the day [2][5][6][8] Chemical Sector Insights - The chemical sector is experiencing a strong upward cycle, driven by increased demand for lithium batteries and phosphorous chemicals, with key materials seeing a surge in prices [9][10] - Major stocks in the chemical sector, such as Enjie Co., Ltd. and Zhejiang Longsheng, reported significant gains, with some stocks rising over 6% [6][8] Non-Ferrous Metals Sector - The non-ferrous metals ETF (159876) demonstrated resilience, closing up 0.18% despite initial declines, supported by over 100 billion yuan in inflows [3][11] - The sector is expected to maintain high profitability over the next 3-5 years, driven by supply-demand dynamics and macroeconomic conditions [11] Hong Kong Market Dynamics - The Hong Kong market saw a significant influx of southbound capital, with purchases reaching 133.7 billion HKD, 249.8 billion HKD, and 148.6 billion HKD over three days [4] - The pharmaceutical sector in Hong Kong showed signs of recovery, with the Hong Kong Innovation Drug ETF (520880) rising by 2% during the day, driven by strong earnings forecasts from key companies [15][16] Investment Opportunities - Analysts suggest focusing on leading companies in the chemical sector and those benefiting from rising prices, with recommendations to invest through the chemical ETF (516020) for higher efficiency [10][21] - The Hong Kong Innovation Drug ETF (520880) and the Hong Kong Medical ETF (159137) are highlighted as attractive options for investors looking to capitalize on the pharmaceutical sector's growth [20][21]

Group 1 - Lee & Man Paper (02314) has seen its stock price rise by over 30% year-to-date, with expected profits of approximately HKD 1.88 billion to HKD 2.00 billion in 2025, representing a year-on-year growth of 38% to 47% due to increased marginal profits [1] - Soundon Technology (02495) shares rose over 8.8% after winning a contract worth nearly RMB 300 million for an AI project in Sichuan province [1] - Zhongxin Innovation (03931) stock increased by over 3.8%, with a reported 630% year-on-year growth in commercial battery deliveries in January 2026, indicating a strong market strategy and capacity layout [1] Group 2 - Tea stocks experienced a rise, with Gu Ming (01364) up 4.12%, Cha Bai Dao (02555) up 3.74%, and others benefiting from a promotional campaign offering free milk tea at over 300,000 stores nationwide [2] - Innovent Biologics (09969) shares surged over 11% after announcing expected revenues of RMB 2.37 billion in 2025, a 134% increase, and a projected net profit of around RMB 630 million [2] - Jun Da Holdings (02865) rebounded over 4.6% following news of the U.S. Federal Communications Commission accepting SpaceX's data center application [2] Group 3 - Li Auto-W (02015) shares rose over 5.3% as the CEO teased the new Li L9 model, emphasizing the importance of AI in enhancing vehicle value [3] - JX International Resources (03858) saw a stock increase of over 4.6% as tungsten prices reached a recent high of CNY 1,545,000 per ton, up CNY 25,000 from the previous trading day [3] - Nine Dragons Paper (02689) shares increased by over 5.7% after announcing a profit forecast for FY26H1 of CNY 2.15 billion to CNY 2.25 billion, a year-on-year growth of 216% to 231% [3] Group 4 - Long Resources (01712) stock surged over 35%, reaching a historical high, with expected after-tax profits of AUD 58 million to AUD 62 million for the year ending December 31, 2025, a significant increase from AUD 12.9 million in the previous year [4] Group 5 - Forgent Power Solutions (FPS.US) debuted on the U.S. stock market with a closing increase of 7.41%, focusing on power solutions for data centers [5] - Bob's Discount Furniture (BOBS.US) also entered the market, with a slight increase of 0.12%, managing 206 showrooms across 26 states and projecting revenues of USD 2.32 billion for FY2025 [5] Group 6 - Eikon Therapeutics (EIKN.US) fell over 16.67% on its Nasdaq debut, focusing on cancer therapies with a candidate drug in mid-stage trials [6] - Cryptocurrency stocks saw significant declines, with Hut 8 (HUT.US) down 17.89% and others following suit amid a Bitcoin sell-off, which dropped nearly 10% [6] Group 7 - Major U.S. indices opened lower, with the Nasdaq down 1.6%, and notable tech stocks like Amazon (AMZN.US) and Tesla (TSLA.US) also declining [7] - Estée Lauder (EL.US) dropped nearly 19.19% despite meeting sales expectations, reflecting market volatility [7] Group 8 - NIO (NIO.US) shares rose 5.86% after announcing an expected adjusted operating profit of between RMB 700 million and RMB 1.2 billion for Q4 2025, marking its first quarterly adjusted operating profit [8] - Hims & Hers Health (HIMS.US) initially surged nearly 14% before closing down 3.77%, launching a new generic medication at a competitive price [9] - Qualcomm (QCOM.US) fell 8.46% amid concerns over weak earnings forecasts related to chip shortages affecting smartphone demand [9]

来源：滚动播报 港股午间收盘，恒生科技指数跌0.47%，恒生指数跌1.13%。恒指港股通ETF银华（159318）跌0.92%， 港股通科技ETF鹏华（159751）涨0.2%。板块方面，建筑产品、汽车板块涨幅靠前；酒店和度假村 REIT、客运航空公司板块跌幅靠前。个股方面，CMON大涨超73%；理想汽车-W涨5.28%，牧原股份涨 4.51%；德林控股跌4.97%，MIRXES-B跌10.54%；诺诚健华涨11.74%，长飞光纤光缆涨9.83%。 ...

Market Overview - The Hang Seng Index fell by 1.13%, down 304 points, closing at 26,580 points, while the Hang Seng Tech Index decreased by 0.47% [1] - The early trading volume in Hong Kong stocks reached HKD 139.5 billion [1] New Listings and Performance - Dazhu CNC (301200) (03200) rose by 18%, recognized as China's largest manufacturer of PCB production equipment [1] - Muyuan Foods (002714) (02714) increased by 4.72% [1] - Zhuozheng Medical (02677) surged by 34%, focusing on the mid-to-high-end medical service market [1] Company Highlights - Zhongchuang Innovation (03931) saw a 3.83% increase, with a 630% year-on-year growth in commercial battery deliveries and plans for full circulation of H-shares [1] - Alibaba's Qianwen event completed over one million milk tea orders, boosting shares of Guming (01364) and Cha Baidao (02555) by over 3% [1] - Long Resources (01712) experienced a 30% intraday surge, with expected after-tax net profit growth of up to 3.8 times year-on-year [1] - Changfei Optical Fiber (601869) saw its shares rise by over 10%, with institutions optimistic about fiber optic manufacturers benefiting from price increases [1] - Innovent Biologics (09969) increased by over 11%, achieving profitability for the first time due to the volume of Orelabrutinib and growth in BD revenue [1] - Nine Dragons Paper (02689) rose by over 5%, benefiting from improved self-sufficiency in wood pulp and favorable industry supply-demand dynamics [1] - Jiaxin International Resources (03858) increased by over 5%, supported by supply contraction driving tungsten prices higher [1] - Fuhong Hanlin (02696) rose by over 5%, with a transaction worth approximately USD 388 million for the licensing of Hansoh's rights in Japan to Eisai [1] - Tongda Group (00698) increased by over 6%, expecting to turn a profit of up to HKD 125 million last year [1] - NIO-SW (09866) rose by over 5%, marking its first quarterly profit with an expected adjusted operating profit of up to HKD 1.2 billion [1] Cryptocurrency Market - Cryptocurrency ETFs and related stocks continued to decline, with a sustained sell-off in the crypto market, as Bitcoin fell below USD 65,000 [1] - Bosera Bitcoin (03008) dropped by 8%, while Huaxia Bitcoin (03042) fell by 9% [1]

Group 1 - The Hang Seng Index fell by 1.13%, down 304 points, closing at 26,580 points, while the Hang Seng Tech Index decreased by 0.47% [1] - Three new stocks were listed: Dazhu CNC (03200) rose by 18%, Muyuan Foods (02714) increased by 4.72%, and Zhuozheng Medical (02677) surged by 34% [1] - Zhongxin Hang (03931) saw a 3.83% increase, with a 630% year-on-year growth in commercial battery deliveries and plans for full circulation of H-shares [1] - Long Resources (01712) experienced a 30% intraday surge, with expected net profit growth of up to 3.8 times year-on-year [1] - Changfei Optical Fiber (06869) rose over 10%, with institutions optimistic about fiber optic manufacturers benefiting from price increases [1] - Nuo Cheng Jianhua (09969) increased by over 11%, achieving profitability for the first time due to the volume of Obutinin and growth in BD revenue [1] - Nine Dragons Paper (02689) rose over 5%, benefiting from improved self-sufficiency in wood pulp and favorable industry supply-demand dynamics [1] - Jiaxin International Resources (03858) increased by over 5%, supported by supply contraction driving up tungsten prices [1] Group 2 - Fuhong Hanlin (02696) rose over 5% after licensing rights to Hanshuo in Japan to Eizai for a total transaction amount of approximately $388 million [2] Group 3 - Tongda Group (00698) increased by over 6%, expecting to turn a profit with a maximum earnings forecast of 125 million HKD for the previous year [3] - NIO-SW (09866) rose over 5%, marking its first quarterly profit with an expected adjusted operating profit of up to 1.2 billion CNY for the last quarter [3] - Cryptocurrency ETFs and related stocks continued to decline, with Bitcoin dropping below $65,000 amid ongoing sell-offs in the crypto market [3]

港股创新药概念股震荡走高，诺诚健华涨超10%，歌礼制药-B涨超8%，山东新华制药、昭衍新药、信 达生物跟涨。 ...

Group 1 - The Hong Kong stock market for innovative drug concept stocks has experienced a significant upward trend, with notable gains in several companies [1] - Nocare Pharma (09969.HK) has seen an increase of over 10%, while Genscript Biotech (01672.HK) has risen by more than 7% [1] - Other companies such as Kelun-Biotech (06990.HK), Sihuan Pharmaceutical (02096.HK), and WuXi AppTec (02359.HK) have also followed suit with upward movements in their stock prices [1]

消息面上，诺诚健华发布盈喜，预计2025年实现收入23.7亿元，同比增长约134%；预计2025年归母净 利润首次扭亏为盈，达6.3亿元左右。业绩增长主要因为公司药品收入持续快速增长及BD收入增长。 2025年，公司持续推进全球化进程，全年达成两项BD交易。 诺诚健华(09969)再涨超11%，截至发稿，涨11.08%，报13.15港元，成交额1.55亿港元。 平安证券表示，公司核心品种奥布替尼稳步放量，围绕血液瘤、自免、实体瘤领域全方位布局，稳步推 进在研管线。此外公司积极开展对外合作，2025年达成两项对外授权合作交易，对应首付款及未来里程 碑收入确认，上调2025-2027年收入预测至23.71、25.75、27.32亿元，2025-2027年公司收入增速分别为 134.9%/8.6%/6.1%，维持"推荐"评级。 ...

平安证券表示，公司核心品种奥布替尼稳步放量，围绕血液瘤、自免、实体瘤领域全方位布局，稳步推 进在研管线。此外公司积极开展对外合作，2025年达成两项对外授权合作交易，对应首付款及未来里程 碑收入确认，上调2025-2027年收入预测至23.71、25.75、27.32亿元，2025-2027年公司收入增速分别为 134.9%/8.6%/6.1%，维持"推荐"评级。 消息面上，诺诚健华发布盈喜，预计2025年实现收入23.7亿元，同比增长约134%；预计2025年归母净 利润首次扭亏为盈，达6.3亿元左右。业绩增长主要因为公司药品收入持续快速增长及BD收入增长。 2025年，公司持续推进全球化进程，全年达成两项BD交易。 智通财经APP获悉，诺诚健华(09969)再涨超11%，截至发稿，涨11.08%，报13.15港元，成交额1.55亿港 元。 ...

每经AI快讯，2月6日，创新药概念盘中震荡反弹， 广生堂涨超10%，诺诚健华、舒泰神、科伦药业、 三生国健、美迪西、诺思兰德冲高。 （文章来源：每日经济新闻） ...